CD33 and neoplasm: Because CD33 is a notable and promising myeloid-specific target, many groups have independently designed CD33-directed CAR T cells (in Fig. 2) and reported potent anti-leukemia outcomes using AML tumor cells and primary xenograft models [63–68].